Cargando…

Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis

BACKGROUND AND AIM: Liver histology changes are the current gold standard for evaluating non‐alcoholic steatohepatitis (NASH), but are limited by their invasiveness and variability for sampling and interpretation. We evaluated noninvasive biomarkers as an indication of histologic changes in NASH. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davison, Beth A, Edwards, Christopher, Loomba, Rohit, Harrison, Stephen A, Cotter, Gad, Alkhouri, Naim, Koch, Gary G, Dittrich, Howard C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264234/ https://www.ncbi.nlm.nih.gov/pubmed/34263067 http://dx.doi.org/10.1002/jgh3.12575

Ejemplares similares

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
por: Alkhouri, Naim, et al.
Publicado: (2021)

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020)

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
por: Dufour, Jean-François, et al.
Publicado: (2020)

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints
por: Alkhouri, Naim, et al.
Publicado: (2019)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
por: Loomba, Rohit
Publicado: (2021)

Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis
por: Carlsson, Björn, et al.
Publicado: (2020)

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
por: Sinakos, Emmanouil, et al.
Publicado: (2022)

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2023)

Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis
por: Waghorn, Philip A., et al.
Publicado: (2021)

Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis
por: Biberci Keskin, Elmas, et al.
Publicado: (2019)

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
por: Younossi, Zobair M., et al.
Publicado: (2021)

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH
por: Harrison, Stephen A., et al.
Publicado: (2021)

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
por: Brennan, Paul N., et al.
Publicado: (2023)

Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD
por: Pearce, Steven G, et al.
Publicado: (2013)

Author Correction: Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis
por: Waghorn, Philip A., et al.
Publicado: (2021)

Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis
por: Sharpton, Suzanne R., et al.
Publicado: (2022)

Vasodilators in the treatment of acute heart failure: what we know, what we don’t
por: Metra, Marco, et al.
Publicado: (2008)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
por: Federico, Alessandro, et al.
Publicado: (2021)

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
por: Jacobson, Ira M., et al.
Publicado: (2022)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
por: Weinmann, Arndt, et al.
Publicado: (2015)

Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis
por: Chung, Goh Eun, et al.
Publicado: (2013)

Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid
por: Yoo, Wonbeak, et al.
Publicado: (2017)

Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma
por: Takakura, Kazuki, et al.
Publicado: (2019)

Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis
por: Kakehashi, Anna, et al.
Publicado: (2023)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Formulation for Effective Screening and Management of Nonalcoholic Steatohepatitis: Noninvasive NAFLD Management Strategy
por: Hirose, Kanae, et al.
Publicado: (2016)

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
por: Lawitz, Eric, et al.
Publicado: (2022)

Effect of systemic corticosteroid therapy for acute heart failure patients with elevated C‐reactive protein
por: Miró, Òscar, et al.
Publicado: (2022)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
por: Tovo, Cristiane Valle, et al.
Publicado: (2023)

Endothelial dysfunction in patients with non-alcoholic steatohepatitis
por: Onal, Ibrahim Koral
Publicado: (2014)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management
por: Salomone, Federico, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1p3g4a2chpl0f5jb2bd522300m